AnaptysBio, Inc.

NASDAQ:ANAB

35.9 (USD) • At close September 6, 2024
Bedrijfsnaam AnaptysBio, Inc.
Symbool ANAB
Munteenheid USD
Prijs 35.9
Beurswaarde 1,084,172,820
Dividendpercentage 0%
52-weken bereik 13.36 - 41.308
Industrie Biotechnology
Sector Healthcare
CEO Mr. Daniel R. Faga
Website https://www.anaptysbio.com

An error occurred while fetching data.

Over AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through

Vergelijkbare Aandelen

Vaxxinity, Inc. logo

Vaxxinity, Inc.

VAXX

0.04 USD

Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Inc.

VNDA

5.02 USD

UFP Technologies, Inc. logo

UFP Technologies, Inc.

UFPT

321.24 USD

Quantum-Si incorporated logo

Quantum-Si incorporated

QSI

0.911 USD

Orthofix Medical Inc. logo

Orthofix Medical Inc.

OFIX

16.24 USD

Humacyte, Inc. logo

Humacyte, Inc.

HUMA

5.27 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

5.42 USD

Collegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc.

COLL

37.19 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)